

# Gouri Yogalingam

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1904338/publications.pdf>

Version: 2024-02-01

12  
papers

472  
citations

933447

10  
h-index

1281871

11  
g-index

13  
all docs

13  
docs citations

13  
times ranked

647  
citing authors

#	ARTICLE	IF	CITATIONS
1	Intracerebroventricular enzyme replacement therapy with $\beta$ -galactosidase reverses brain pathologies due to GM1 gangliosidosis in mice. <i>Journal of Biological Chemistry</i> , 2020, 295, 13532-13555.	3.4	30
2	Intermittent enzyme replacement therapy with recombinant human $\beta$ -galactosidase prevents neuraminidase 1 deficiency. <i>Journal of Biological Chemistry</i> , 2020, 295, 13556-13569.	3.4	10
3	Differential Uptake of NAGLU-IGF2 and Unmodified NAGLU in Cellular Models of Sanfilippo Syndrome Type B. <i>Molecular Therapy - Methods and Clinical Development</i> , 2019, 14, 56-63.	4.1	12
4	BMN 250, a fusion of lysosomal alpha-N-acetylglucosaminidase with IGF2, exhibits different patterns of cellular uptake into critical cell types of Sanfilippo syndrome B disease pathogenesis. <i>PLoS ONE</i> , 2019, 14, e0207836.	2.5	18
5	Characterization of glycan substrates accumulating in GM1 Gangliosidosis. <i>Molecular Genetics and Metabolism Reports</i> , 2019, 21, 100524.	1.1	15
6	Cellular Uptake and Delivery of Myeloperoxidase to Lysosomes Promote Lipofuscin Degradation and Lysosomal Stress in Retinal Cells. <i>Journal of Biological Chemistry</i> , 2017, 292, 4255-4265.	3.4	17
7	Clearance of Heparan Sulfate and Attenuation of CNS Pathology by Intracerebroventricular BMN 250 in Sanfilippo Type B Mice. <i>Molecular Therapy - Methods and Clinical Development</i> , 2017, 6, 43-53.	4.1	34
8	Neuraminidase 1 Is a Negative Regulator of Lysosomal Exocytosis. <i>Developmental Cell</i> , 2008, 15, 74-86.	7.0	136
9	Arylase (Biomarin). <i>Current Opinion in Investigational Drugs</i> , 2004, 5, 1111-20.	2.3	0
10	Molecular genetics of mucopolysaccharidosis type IIIA and IIIB: Diagnostic, clinical, and biological implications. <i>Human Mutation</i> , 2001, 18, 264-281.	2.5	153
11	Mucopolysaccharidosis type IIIB: characterisation and expression of wild-type and mutant recombinant $\beta$ -N-acetylglucosaminidase and relationship with Sanfilippo phenotype in an attenuated patient. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2000, 1502, 415-425.	3.8	29
12	Mild Feline Mucopolysaccharidosis Type VI. <i>Journal of Biological Chemistry</i> , 1998, 273, 13421-13429.	3.4	18